Immunocore Holdings plcIMCR
What Immunocore Holdings plc does.
We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging our proprietary, flexible, off-the-shelf ImmTAX ® ( I mmune m obilizing m onoclonal T CRs A gainst X disease) platform, we are developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and earlier pre-clinical programs across three therapeutic areas.
In 2022, we received approval for our lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma ("mUM") from the FDA, the European Commission and other health authorities. KIMMTRAK is now approved in 39 countries and the Company has commercially launched the product in 30 countries, including the United States, Germany and France, among other territories.
KIMMTRAK is the lead product from our ImmTAX platform and was the first approved therapy in mUM. To date, we have treated over 2,000 cancer patients with KIMMTRAK (tebentafusp), and our other ImmTAX product candidates, which we believe is the largest clinical data set of any T cell engager bispecific in solid tumors and any T cell receptor ("TCR") therapeutic. Our clinical programs are being conducted with patients with a broad range of cancers including melanoma, ovarian, lung, and colorectal, among others. We believe that these tumor types have large addressable patient populations and significant unmet need. We are progressing three late-stage clinical programs within our ImmTAC ® ( I mmune m obilizing m onoclonal T CRs A gainst C ancer) portfolio, including KIMMTRAK and the PRAME-targeted brenetafusp.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $36.5M | $174.4M | $249.4M | $310.2M | $400.0M |
| Net income | — | -$180.0M | -$52.5M | -$55.3M | -$51.1M | -$35.5M |
| Free cash flow | — | -$144.5M | -$51.4M | -$2.5M | $20.9M | -$15.1M |
More on IMCR.
- Immunocore Holdings plc summary
- Immunocore Holdings plc financial statements
- Immunocore Holdings plc key metrics
- Immunocore Holdings plc health scores and style box
- Immunocore Holdings plc earnings
- Immunocore Holdings plc dividends
- Immunocore Holdings plc valuation
- Immunocore Holdings plc ownership and insiders
- Immunocore Holdings plc peers
Figures from Immunocore Holdings plc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.